Proteomika has ordered novel, HuCAL-based, research antibodies against a broad range of target molecules in addition to the production of antigen material at AbD Serotec. The order ranks Proteomika among the largest customers for custom monoclonals services provided by AbD Serotec.
Laureano Simon, CEO of Proteomika, said: “The fast turn around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of biomarker identification and validation, allowing Proteomika to bring new diagnostic and prognostic tools for human diseases to the market in the shortest possible timeframe.”